• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

改善心力衰竭管理的新基础科学见解:意大利心脏病学会心脏细胞和分子生物学工作组综述。

Novel Basic Science Insights to Improve the Management of Heart Failure: Review of the Working Group on Cellular and Molecular Biology of the Heart of the Italian Society of Cardiology.

机构信息

IRCCS Ospedale Policlinico San Martino-IRCCS Italian Cardiovascular Network & Department of Internal Medicine, University of Genova, 16132 Genova, Italy.

Department of Internal Medicine (Cardiology), University of Texas Southwestern Medical Center, Dallas, TX 75206, USA.

出版信息

Int J Mol Sci. 2020 Feb 11;21(4):1192. doi: 10.3390/ijms21041192.

DOI:10.3390/ijms21041192
PMID:
32054029
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7072832/
Abstract

Despite important advances in diagnosis and treatment, heart failure (HF) remains a syndrome with substantial morbidity and dismal prognosis. Although implementation and optimization of existing technologies and drugs may lead to better management of HF, new or alternative strategies are desirable. In this regard, basic science is expected to give fundamental inputs, by expanding the knowledge of the pathways underlying HF development and progression, identifying approaches that may improve HF detection and prognostic stratification, and finding novel treatments. Here, we discuss recent basic science insights that encompass major areas of translational research in HF and have high potential clinical impact.

摘要

尽管在诊断和治疗方面取得了重要进展,但心力衰竭(HF)仍然是一种发病率高、预后不良的综合征。尽管现有技术和药物的实施和优化可能会导致 HF 得到更好的管理,但仍需要新的或替代的策略。在这方面,基础科学有望通过扩展 HF 发展和进展的潜在途径的知识,确定可能改善 HF 检测和预后分层的方法,并寻找新的治疗方法,为其提供基本的投入。在这里,我们讨论了最近的基础科学见解,这些见解涵盖了 HF 转化研究的主要领域,具有很高的临床应用潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e91/7072832/45cd097d15de/ijms-21-01192-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e91/7072832/93699e4bb55b/ijms-21-01192-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e91/7072832/4ac31e20dab4/ijms-21-01192-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e91/7072832/45cd097d15de/ijms-21-01192-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e91/7072832/93699e4bb55b/ijms-21-01192-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e91/7072832/4ac31e20dab4/ijms-21-01192-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e91/7072832/45cd097d15de/ijms-21-01192-g003.jpg

相似文献

1
Novel Basic Science Insights to Improve the Management of Heart Failure: Review of the Working Group on Cellular and Molecular Biology of the Heart of the Italian Society of Cardiology.改善心力衰竭管理的新基础科学见解:意大利心脏病学会心脏细胞和分子生物学工作组综述。
Int J Mol Sci. 2020 Feb 11;21(4):1192. doi: 10.3390/ijms21041192.
2
Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology.靶向心肌重构以开发心力衰竭的新疗法:欧洲心脏病学会心肌功能工作组的立场文件。
Eur J Heart Fail. 2014 May;16(5):494-508. doi: 10.1002/ejhf.62. Epub 2014 Mar 17.
3
The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.自主神经系统作为心力衰竭的治疗靶点:欧洲心脏病学会心力衰竭协会转化研究委员会的科学立场声明。
Eur J Heart Fail. 2017 Nov;19(11):1361-1378. doi: 10.1002/ejhf.921. Epub 2017 Sep 26.
4
Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups.欧洲心脏病学会成员国心力衰竭管理组织:欧洲心脏病学会心力衰竭协会与心力衰竭国家学会/工作组合作调查。
Eur J Heart Fail. 2013 Sep;15(9):947-59. doi: 10.1093/eurjhf/hft092. Epub 2013 Jun 19.
5
Heart failure biomarkers.心力衰竭生物标志物。
J Cardiovasc Transl Res. 2013 Aug;6(4):471-84. doi: 10.1007/s12265-013-9465-0. Epub 2013 Apr 20.
6
Heart failure research: translating basic science into therapies.心力衰竭研究:将基础科学转化为治疗方法。
Methodist Debakey Cardiovasc J. 2009;5(3):38-41. doi: 10.14797/mdcj-5-3-38.
7
Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding.HFpEF 和 HFrEF 之间的细胞和分子差异:在改善病理认识方面迈出的一步。
Cells. 2020 Jan 18;9(1):242. doi: 10.3390/cells9010242.
8
Gene therapy in heart failure. SERCA2a as a therapeutic target.心力衰竭中的基因治疗。将肌浆网Ca2+-ATP酶2a作为治疗靶点。
Circ J. 2014;78(11):2577-87. doi: 10.1253/circj.cj-14-1053. Epub 2014 Oct 18.
9
Regulation of Mitochondrial Function by Noncoding RNAs in Heart Failure and Its Application in Diagnosis and Treatment.非编码 RNA 对心力衰竭中线粒体功能的调控及其在诊断和治疗中的应用。
J Cardiovasc Pharmacol. 2021 Sep 1;78(3):377-387. doi: 10.1097/FJC.0000000000001081.
10
Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology.为了更好地定义、量化和治疗心力衰竭中的纤维化。欧洲心脏病学会心力衰竭协会(HFA)转化研究委员会的科学路线图。
Eur J Heart Fail. 2019 Mar;21(3):272-285. doi: 10.1002/ejhf.1406. Epub 2019 Feb 4.

引用本文的文献

1
The treatment with trandolapril and losartan attenuates pressure and volume overload alternations of cardiac connexin-43 and extracellular matrix in Ren-2 transgenic rats.曲美他嗪联合氯沙坦治疗可减轻 Ren-2 转基因大鼠心脏缝隙连接蛋白 43 和细胞外基质的压力和容量超负荷改变。
Sci Rep. 2023 Nov 27;13(1):20923. doi: 10.1038/s41598-023-48259-2.
2
Forkhead box O6 (FoxO6) promotes cardiac pathological remodeling and dysfunction by activating Kif15-TGF-β1 under aggravated afterload.叉头框O6(FoxO6)通过在加重的后负荷下激活Kif15-转化生长因子-β1(Kif15-TGF-β1)来促进心脏病理重塑和功能障碍。
MedComm (2020). 2023 Oct 3;4(5):e383. doi: 10.1002/mco2.383. eCollection 2023 Oct.
3

本文引用的文献

1
Female Sex Is Protective in a Preclinical Model of Heart Failure With Preserved Ejection Fraction.在射血分数保留的心力衰竭临床前模型中,女性具有保护作用。
Circulation. 2019 Nov 19;140(21):1769-1771. doi: 10.1161/CIRCULATIONAHA.119.042267. Epub 2019 Nov 18.
2
The gut microbiome and heart failure: A better gut for a better heart.肠道微生物组与心力衰竭:更好的肠道,更好的心脏。
Rev Endocr Metab Disord. 2019 Dec;20(4):407-414. doi: 10.1007/s11154-019-09519-7.
3
Cardiovascular nanomedicine: the route ahead.心血管纳米医学:未来之路
From Genetic Mutations to Molecular Basis of Heart Failure Treatment: An Overview of the Mechanism and Implication of the Novel Modulators for Cardiac Myosin.
从基因突变到心力衰竭治疗的分子基础:新型肌球蛋白调节剂作用机制及意义概述。
Int J Mol Sci. 2021 Jun 21;22(12):6617. doi: 10.3390/ijms22126617.
4
The Neuroimmune Role of Intestinal Microbiota in the Pathogenesis of Cardiovascular Disease.肠道微生物群在心血管疾病发病机制中的神经免疫作用
J Clin Med. 2021 May 6;10(9):1995. doi: 10.3390/jcm10091995.
5
Exploring the Potential Role of the Gut Microbiome in Chemotherapy-Induced Neurocognitive Disorders and Cardiovascular Toxicity.探索肠道微生物群在化疗引起的神经认知障碍和心血管毒性中的潜在作用。
Cancers (Basel). 2021 Feb 13;13(4):782. doi: 10.3390/cancers13040782.
Nanomedicine (Lond). 2019 Sep;14(18):2391-2394. doi: 10.2217/nnm-2019-0228. Epub 2019 Aug 28.
4
Diet, the Gut Microbiome and Heart Failure.饮食、肠道微生物群与心力衰竭
Card Fail Rev. 2019 May 24;5(2):119-122. doi: 10.15420/cfr.2018.39.2. eCollection 2019 May.
5
2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy.2019 HRS 专家共识声明:心律失常性心肌病的评估、风险分层和管理。
Heart Rhythm. 2019 Nov;16(11):e301-e372. doi: 10.1016/j.hrthm.2019.05.007. Epub 2019 May 9.
6
Current Landscape of Heart Failure Gene Therapy.心力衰竭基因治疗的现状
J Am Heart Assoc. 2019 May 21;8(10):e012239. doi: 10.1161/JAHA.119.012239.
7
Nitrosative stress drives heart failure with preserved ejection fraction.硝化应激导致射血分数保留型心力衰竭。
Nature. 2019 Apr;568(7752):351-356. doi: 10.1038/s41586-019-1100-z. Epub 2019 Apr 10.
8
The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity.新型丁酸盐衍生物苯丙氨酸丁酰胺可预防阿霉素引起的心脏毒性。
Eur J Heart Fail. 2019 Apr;21(4):519-528. doi: 10.1002/ejhf.1439. Epub 2019 Mar 6.
9
Short-Chain Fatty Acid Propionate Protects From Hypertensive Cardiovascular Damage.短链脂肪酸丙酸盐可预防高血压性心血管损伤。
Circulation. 2019 Mar 12;139(11):1407-1421. doi: 10.1161/CIRCULATIONAHA.118.036652.
10
Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure.卡那奴单抗的抗炎治疗预防心力衰竭住院。
Circulation. 2019 Mar 5;139(10):1289-1299. doi: 10.1161/CIRCULATIONAHA.118.038010.